Truist Securities raised Gilead Sciences, Inc. (GILD) price target to $145 from $140, maintaining a Buy rating. Citigroup also increased target to $156 from $140. GILD is a biopharmaceutical company developing medicines for HIV, viral hepatitis, and cancer. Investors are optimistic about GILD’s potential amidst promising Q4 previews for biopharmaceutical stocks.

Read more at Yahoo Finance: Truist Securities Raises Price Target on Gilead Sciences, Inc. (GILD) to $145, Keeps Buy Rating